Tools to implement the World Health Organization End TB Strategy:Addressing common challenges in high and low endemic countries by Al Abri, Seif et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Tools to implement the World Health Organization End TB Strategy
Addressing common challenges in high and low endemic countries
Al Abri, Seif; Kasaeva, Thereza; Migliori, Giovanni Battista; Goletti, Delia; Zenner, Dominik;
Denholm, Justin; Al Maani, Amal; Cirillo, Daniela Maria; Schon, Thomas; Lillebæk, Troels; Al-
Jardani, Amina; Go, Un-Yeong; Dias, Hannah Monica; Tiberi, Simon; Al Yaquobi, Fatma;
Khamis, Faryal Ali; Kurup, Padmamohan; Wilson, Michael; Memish, Ziad; Al Maqbali, Ali;
Akhtar, Muhammad; Wejse, Christian; Petersen, Eskild
Published in:






Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Al Abri, S., Kasaeva, T., Migliori, G. B., Goletti, D., Zenner, D., Denholm, J., ... Petersen, E. (2020). Tools to
implement the World Health Organization End TB Strategy: Addressing common challenges in high and low
endemic countries. International Journal of Infectious Diseases, 92, S60-S68.
https://doi.org/10.1016/j.ijid.2020.02.042
Download date: 14. May. 2020
International Journal of Infectious Diseases 92S (2020) S60–S68Tools to implement the World Health Organization End TB
Strategy: Addressing common challenges in high and low
endemic countries
Seif Al Abria,*, Thereza Kasaevab, Giovanni Battista Miglioric, Delia Golettid,e,
Dominik Zennerf, Justin Denholmg, Amal Al Maanih, Daniela Maria Cirilloi,
Thomas Schönj, Troels Lillebækk, Amina Al-Jardanil, Un-Yeong Gom,
Hannah Monica Diasn, Simon Tiberio,p, Fatma Al Yaquobiq, Faryal Ali Khamisr,
Padmamohan Kurups, Michael Wilsont, Ziad Memishu,v, Ali Al Maqbaliw,
Muhammad Akhtarx, Christian Wejsey,z, Eskild PetersenA,B,C
aDirectorate General for Diseases Surveillance and Control, Ministry of Health, Muscat, Oman
bWHO Global TB Programme, Geneva, Switzerland
c Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy
d Translational Research Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” — IRCCS, Rome, Italy
e ESCMID Study Group on Mycobacteria, Basel, Switzerland
fRegional Office of the European Economic Area, EU and NATO and International Organization for Migration, IOM, Brussels, Belgium
gDepartment of Infectious Diseases, Royal Melbourne Hospital and Victorian TB Programme, Melbourne, Australia
h Paediatric Infectious Diseases, The Royal Hospital and Central Department of Infection Prevention and Control, Directorate General for Diseases Surveillance
and Control, Ministry of Health, Muscat, Oman
i Emerging Bacterial Pathogen Research Unit, Italian Reference Centre for Molecular Typing of Mycobacteria, San Rafaele Scientific Institute, Milan, Italy
jDepartment of Clinical Microbiology and Infectious Diseases, Kalmar Hospital and University of Linköping, Sweden
k International Reference Laboratory of Mycobacteriology, WHO TB Supranational Reference Laboratory Copenhagen, Infectious Disease Preparedness Area,
Statens Serum Institute and Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
lCentral Public Health Laboratory, Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman
m International Tuberculosis Research Centre, Seoul, Republic of Korea
nWHO Global TB Programme Unit on Policy, Strategy and Innovations, Geneva, Switzerland
o Infectious Diseases, Barts Health NHS Trust, London, United Kingdom
pQueen Mary University of London, London, United Kingdom
q Tuberculosis and Acute Respiratory Diseases Surveillance, Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman
rDepartment of Infectious Diseases, The Royal Hospital, Ministry of Health, Muscat, Oman
sDepartment of Disease Surveillance and Control, Muscat Governorate, Muscat, Oman
t Zero TB Initiative, Durban, South Africa
u Prince Mohammed bin Abdulaziz Hospital, Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
vRollings School of Public Health, Emory University, Atlanta, GA, USA
wDisease Surveillance and Control, North Bathinah Governorate, Sohar, Oman
xWHO MENA Region TB Programme, Cairo, Egypt
yDepartment of Infectious Disease, Aarhus University Hospital and School of Public Health, Faculty of Health Sciences, University of Aarhus, Denmark
z ESCMID Study Group for Travel and Migration, Basel, Switzerland
ADirectorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman
B Institute for Clinical Medicine, Faculty of Health Science, University of Aarhus, Denmark
C ESCMID Emerging Infections Task Force, Basel, Switzerland
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier .com/ locate / i j id* Corresponding author.
E-mail address: salabri@gmail.com (S. Al Abri).
https://doi.org/10.1016/j.ijid.2020.02.042
1201-9712/© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
S. Al Abri et al. / International Journal of Infectious Diseases 92S (2020) S60–S68 S61A R T I C L E I N F O
Article history:
Received 15 January 2020
Received in revised form 21 February 2020









A B S T R A C T
Aim: The purpose of this viewpoint is to summarize the advantages and constraints of the tools and
strategies available for reducing the annual incidence of tuberculosis (TB) by implementing the World
Health Organization (WHO) End TB Strategy and the linked WHO TB Elimination Framework, with special
reference to Oman.
Methods: The case-study was built based on the presentations and discussions at an international
workshop on TB elimination in low incidence countries organized by the Ministry of Health, Oman, which
took place from September 5 to September 7, 2019, and supported by the WHO and European Society of
Clinical Microbiology and Infectious Diseases (ESCMID).
Results: Existing tools were reviewed, including the screening of migrants for latent TB infection (LTBI)
with interferon-gamma release assays, clinical examination for active pulmonary TB (APTB) including
chest X-rays, organization of laboratory services, and the existing centres for mandatory health
examination of pre-arrival or arriving migrants, including examination for APTB. The need for public–
private partnerships to handle the burden of screening arriving migrants for active TB was discussed at
length and different models for financing were reviewed.
Conclusions: In a country with a high proportion of migrants from high endemic countries, screening for
LTBI is of high priority. Molecular typing and the development of public–private partnerships are needed.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB) is one of the top 10 causes of death worldwide
and the most important cause of death from an infectious disease,
surpassing HIV/AIDS. In 2018, TB caused an estimated 1.5 million
deaths (range 1.4–1.6 million), including 251 000 deaths among
HIV-positive persons (WHO, 2019). The severity of national TB
epidemiology varies significantly among countries. Worldwide in
2019, there were fewer than 10 new cases per 100 000 population
in most high-income countries, 150–400 in most of the 30 high TB
burden countries, and above 500 in six countries (WHO, 2019).
The World Health Organization (WHO) End TB Strategy aims to
end the global TB epidemic by 2035, reducing global TB incidence
and mortality rates by 90% and 95%, respectively, in 2035 when
compared to 2015 (WHO, 2014; Uplekar et al., 2015; Lönnroth et al.,
2015). In September 2018, the goal of ending TB was elevated to the
highest level at the first-ever UN High Level Meeting on TB in New
York, which brought together heads of states and governments,
who made bold commitments to accelerate the TB response. Oman
is a signatory of the UN High-Level Political Declaration on TB
(WHO, 2017).
The WHO End TB Strategy was developed in parallel with the
Sustainable Development Goals (SDGs), and interventions should
be anchored in the SDGs (Lönnroth et al., 2015; Lönnroth and
Raviglione, 2016). It has been estimated that one quarter of the
world population are latently infected with TB, having a latent TB
infection (LTBI) (Houben and Dodd, 2016), and a recent meta-
analysis of prevalence surveys confirmed that 20–25% globallyFigure 1. Trend in tuberculosis inchave LTBI (Cohen et al., 2019). This is a challenge for both high and
low endemic countries, but it is evident that to reach the goal of TB
elimination, the reservoir of LTBI has to be eliminated or reduced
significantly (WHO, 2015; Petersen et al., 2019; Rosales-Klintz
et al., 2019; Centis et al., 2017).
In view of the progress made in several low-incidence
countries, the WHO joined forces with the European Respiratory
Society to adapt the WHO End TB Strategy and develop a
framework for TB elimination in these countries. Take-up of the
WHO TB Elimination framework has been slow (Matteelli et al.,
2018) and there are few published country experiences, with the
exception of Cyprus, Oman, and Latin America (Al Yaquobi et al.,
2018).
Oman as a pathfinder to TB elimination
Oman is a low TB incidence country, with an annual incidence
rate of less than 5.9 cases per 100 000 population in 2018
(Figure 1). Forty-five percent of the population are migrants from
high-incidence countries, i.e. more than 100 cases per year per
100 000 population, accounting for 60% of the annual TB cases
(Table 1; Figure 2). However, several studies have indicated that
incidence rates based on notified cases may not fully reflect the
burden due to under-reporting (Snow et al., 2018; Pandey et al.,
2017; Romanowski et al., 2019).
The purpose of this viewpoint is to summarize the advantages
and constraints of the tools and strategies available for reducing
the annual incidence of TB by implementing the WHO End TBidence in Oman—1981–2018.
Table 1
New tuberculosis cases in Omani nationals and migrants.
Year 2010 2011 2012 2013 2014 2015 2016 2017 2018
Omani nationals 214 239 245 188 184 180 190 141 98
Non-Omanis 94 98 141 146 170 147 154 122 145
Nationals per 105 10.3 11.2 11.7 8.7 8.1 7.7 6.3 4.7 3.3
Non-nationals per 105 8.1 7.1 9.2 8.7 9.8 8.1 7.7 7.1 7.3
Note: Estimated population January 1, 2019: 4 992 364 of which 2994 601 were Omani nationals and 1 997 763 were migrants (National Centre for Statistics and Information).
Figure 2. Age-specific annual tuberculosis incidence in Omani nationals and non-Omanis.
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special reference to Oman. In Oman, a reduction in annual TB
incidence from 59 per million inhabitants (2018) to 1 per million by
2035 has to be achieved, which is the threshold defining TB
elimination (Lönnroth et al., 2015). It may be possible to advance
the elimination date if modelling and effective implementation of
key interventions, including the roll-out of TB preventive
treatment, are conducted.
Methods
The case-study was built based on the presentations and
discussions at an international workshop on TB elimination in low
incidence countries organized by the Ministry of Health, Oman,
which took place from September 5 to September 7, 2019, and
supported by the WHO and the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID).
The meeting reviewed existing tools, including the screening of
migrants for LTBI with interferon-gamma release assays (IGRAs),
clinical examination for active pulmonary TB (APTB) including
chest X-rays (CXR), the organization of laboratory services, and the
existing centres for mandatory health examination of arriving
migrants including examination for APTB. The need for public–
private partnerships to handle the burden of screening arriving
migrants for active TB was discussed at length and different models
for financing were reviewed.
The TB elimination framework programme for Oman has
opened many topics for applied research. It has also allowed the
evaluation of models for public–private partnerships, community
support in the treatment LTBI, the evaluation of screening methods
for LTBI through long-term follow-up, and comparison of different
regimens for the treatment of LTBI, for instance 4 weeks and 12
weeks rifapentin/isoniazid (or rifampicin/isoniazid).A writing team of global TB experts was invited to summarize
the available evidence for the different areas with a non-systematic
approach and to discuss this evidence based on Oman-specific
data. Several rounds of discussion were organized to reach
consensus on the final document.
Background
In 1981, the annual incidence of TB in Oman was over 90 per
100 000 population (Figure 1). Following rapid economic develop-
ment in the 1980s, the incidence declined significantly to 20 per
100 000 population in 1991 and 10 per 100 000 population in 2010
(Ministry of Health, 2018). Over the same period, the proportion of
migrants from high TB endemic countries in Africa and Asia increased
to around 45% of the population. Up until 2017, the national policy for
TB control was based on the screening of migrants on arrival for APTB
with a CXR. Since 2017, investigations for APTB have also included
sputum microscopy, culture, and PCR if there is a clinical or
radiological suspicion of TB. Pre-arrival screening is also conducted
in Gulf Collaboration Council certified centres in the country of origin
of migrants for around 90% of the migrants.
The proportions of APTB cases among Omani nationals and non-
nationals have been changing, with a decreasing number in
Omanis and an increasing number diagnosed in non-Omanis
(Table 1). The stable incidence rate for migrants and the slow
decrease in rate for Omani nationals over the last 10 years
potentially reflect Mycobacterium tuberculosis (Mtb) transmission
from the migrant population (Aldridge et al., 2016), but that
assumption needs to be confirmed by genotyping. TB in migrants
comprises either reactivation of LTBI, diagnosed some years after
entry, or cases missed by the pre-entry or at-entry screening.
It is often held that new cases of TB that occur some years after
entry could be the result of the reactivation of LTBI (Aldridge et al.,
Table 2
Pillars of the End TB strategy.
Integrated, patient-centred care and prevention
1. Early diagnosis of tuberculosis including universal drug-susceptibility testing, and systematic screening of contacts and high-risk groups
2. Treatment of all people with tuberculosis including drug-resistant tuberculosis, and patient support
3. Collaborative tuberculosis/HIV activities, and management of comorbidities
4. Preventive treatment of persons at high risk, and vaccination against tuberculosis
Bold policies and supportive systems
5. Political commitment with adequate resources for tuberculosis care and prevention
6. Engagement of communities, civil society organizations, and public and private care providers
7. Universal health coverage policy, and regulatory frameworks for case notification, vital registration, quality and rational use of medicines, and infection control
8. Social protection, poverty alleviation and actions on other determinants of tuberculosis
Intensified research and innovation
9. Discovery, development and rapid uptake of new tools, interventions and strategies
10. Research to optimize implementation and impact, and promote innovations
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2017; Kamper-Jørgensen et al., 2012a,b). Previous studies have
shown that screening for active TB at entry detects only a small
number of TB cases, but will miss cases reactivating after entry if
screening for LTBI is not included (Abubakar et al., 2011; Kruijshaar
et al., 2013), indicating that screening aimed only at identifying
APTB cases at entry may miss an unknown proportion of cases who
are developing TB at a later point.
The Ministry of Health has estimated that Oman has to reduce
the incidence by around 10% per year to reach the goal of a 90%
reduction in the incidence rate by 2035. To reduce the current
incidence of 59 cases per million population (Table 1) to less than 1
per million by 2035 will pose significant challenges. The age
distribution among non-Omanis is younger than in Omanis, where
older cases are likely more commonly due to reactivation of LTBI
(Figure 2).
Oman fulfils the first three goals of the pillars of the End TB
Strategy (Table 2) and partly also the fourth, “Preventive treatment
of persons at high risk, and vaccination against tuberculosis”, by
including universal bacillus Calmette–Guérin (BCG) immunization
at birth and preventive treatment of contacts of known active TB
cases. The current strategy does not include the screening of
migrants from highly endemic countries for LTBI.
Points 5–8 of the TB Elimination Framework are partly fulfilled
in Oman, in that there is political commitment and universal
government-funded healthcare coverage and regulatory frame-
works for case notification, vital registration, quality and rational
use of medicines, and infection control.
Regarding points 9 and 10, regarding ‘intensified research and
innovation’, this paper will discuss the strategies and tools
available to reduce the incidence in Oman by 10% per year.
A previous modelling study, which reviewed seven different
screening programmes for migrants, found that screening with an
IGRA followed by a short regimen (3 months) of either rifampicin/
isoniazid or rifapentine/isoniazid was the most cost-effective
algorithm in the United Kingdom (Kowada, 2016; Abubakar et al.,
2018). Risk groups among Omani nationals need to be identified
(Katelaris et al., 2019), for instance the elderly, families with
previous TB cases, geographical clustering, and prisons (Noppert
et al., 2019). A study from Japan found that overall population
density, age, and being a healthcare worker (HCW) were risk
factors for TB (Murakami et al., 2019).
Specific interventions for national TB control and elimination
programmes in the End TB era
Multisectoral collaboration and political commitment
TB is a disease of poverty and deprivation, which can only be
controlled by involving multiple stakeholders and addressing the
need of marginalized groups with a high incidence, as recentlyreviewed by the The Lancet Commission on TB (Reid et al., 2019).
The often long incubation period, the latent stage with no
symptoms, and the lack of access to proper diagnostics and
management hamper control efforts. Political commitment is key
to addressing the complex interaction between socio-economic
problems and healthcare provision (Matteelli et al., 2018).
One example is the Zero TB Initiative, which creates support for
local stakeholders helping to mobilize financial and technical
resources. Examples are the mobile units in rural areas of South
Africa providing treatment, and mobile CXR units in Karachi,
Pakistan (Zero TB Initiative). Such outreach is key to reach
marginalized populations and will benefit from a mixture of
private funded and public initiatives.
The government will support policies, which inform migrants
in their own language of their right to seek medical care, the signs
and symptoms of TB, and the right to free treatment in Oman
without the risk of being repatriated in the case of APTB. The End
TB Strategy was reiterated in the Moscow Declaration adopted at
the first WHO Global Ministerial Conference on ending TB in 2017,
where ministers of health (Zumla and Petersen, 2018) including
the minister for Oman, declared “We reaffirm our commitment to
end the TB epidemic by 2030” (WHO, 2017). The Moscow
Declaration called for the development of a multisectoral
accountability framework, which was reiterated in the UN High
Level Meeting Political Declaration by heads of state.
Managing LTBI in migrants
Similar to other countries in the Gulf Cooperation Council,
Oman is characterized by a local population with a low incidence of
TB and a large population of migrants with a higher incidence of TB.
Managing LTBI in this population is a clear priority. The topic was
discussed with focus on both screening and diagnostic challenges,
as well as on treatment (Shete et al., 2018; Wild et al., 2017;
Shedrawy et al., 2017; Zenner et al., 2017; Kunst et al., 2017; Dara
et al., 2017). A study from the Netherlands found that the most
important predictor for developing active TB was known exposure,
but being foreign-born was an independent risk factor (Erkens
et al., 2016), and 72% of new TB cases were foreign-born (van de
Berg et al., 2017).
Diagnosis of LTBI
Mandatory health examinations of migrants in Oman take place
at pre-entry, on arrival, and then every 2–4 years as part of visa
renewal. A CXR is included in these medical examinations,
potentially identifying cases of APTB.
A pilot study from Oman found that 21% of migrants from Asia
and 31% from Africa were IGRA-positive (Yaquobi et al., submitted).
Screening for LTBI is usually performed by tuberculin skin test
(TST) or IGRA, which both detect cell-mediated immune responses
against TB antigens (Getahun et al., 2015; Goletti et al., 2018a,b).
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IGRAs have several advantages compared to TST, they are more
expensive, rely on blood sampling, and require a diagnostic
laboratory (Pai et al., 2014). In immunocompetent subjects, IGRAs
have a very high negative predictive value (NPV; >99%) but as the
tests rely on the cell-mediated immune responses, there is a risk of
false-negatives from immunosuppression. For the QuantiFERON-
TB Gold (QFT) test, there is also increasing awareness that a grey
zone range (at least 0.20–0.70 IU/ml) should be used around the
cut-off (0.35 IU/ml) to avoid both false-negative results due to
recent exposure or immunosuppression and also false-positive
results (Pai et al., 2014). It should be noted that the false-negative
rate of an IGRA in patients with active TB has been reported to be
approximately 12% (Nguyen et al., 2018). Thus IGRA screening for
LTBI may not identify all cases of active TB. However, conversely, a
study from the UK found that pre-entry screening was strongly and
independently associated with fewer APTB cases among new
migrants (Berrocal-Almanza et al., 2019).
Management of LTBI in migrants to Oman
A pragmatic approach to reduce TB incidence could be to select
the migrants with a strongly positive IGRA of >4 IU/ml and offer
them preventive therapy of 3 months of combined rifampicin or
rifapentin and isoniazid.
Two studies (Winje et al., 2018; Andrews et al., 2017) found that
individuals with a strongly positive (>4 IU/ml) IGRA test had a
relative risk of 30 of developing APTB within the next 2 years. A
study from the UK found an approximately five-times higher risk
compared to baseline for developing APTB in subject with a TST
>15 mm, positive T-Spot.TB, or positive IGRA (Abubakar et al.,
2018). However, a follow-up study found that higher thresholds for
QFT, T-Spot.TB, and TST modestly increased the positive predictive
value (PPV) for incident TB, but markedly reduced sensitivity
(Gupta et al., 2019).
In 2018, 943 377 migrants were examined in the medical
migrant examination centres in Oman, and 33% (311 314) of them
were new arrivals. The study of IGRA reactivity in migrants
(Yaquobi et al., submitted) showed that 22.4% had a positive IGRA,
i.e., 69 734 out of the 311 314 new arrivals. Should all 69 734 receive
treatment for latent TB?
Migrants usually stay in Oman for an average of 4 years and it
can be argued that with a low or median reactivity (0.35–4 IU/ml)
and without known risk factors for developing active TB, the
persons should be informed about their status of LTBI and advised
to seek treatment at their own expense. However, we could
consider prioritizing for treatment only migrants with a strongly
positive QFT of >4 IU/ml or those with risk factors (such as
immunosuppression) and a positive QFT (>0.35 IU/ml). This
strategy would reduce the number of persons offered treatment
from 69 734 to 17 224 (24%). This is still a high number, but
distributed in the major cities the task should be manageable in a
public–private partnership programme.
Extending the service by developing public–private partnerships
In 2018, 3 million of the estimated 10 million people with TB
worldwide were ‘missed’ by national TB programmes (NTPs) (WHO,
2019). Two-thirds of them are thought to access TB treatment of
questionable quality from public and private providers who are not
engaged by the NTPs. The quality of care provided in these settings is
often not known or substandard (WHO, 2019). To close these gaps,
the WHO and partners have launched a new roadmap to scale up the
engagementof public and private healthcare providers (WHO, 2018).
Also in Oman, the future challenges of the TB control programme
need resources provided by the private health sector, both in
diagnostics and the management of LTBI.The government is committed to providing treatment for both
LTBI and active TB, to both Omani nationals and migrants. This will
be done either in public or private facilities.
Involvement of the private sector in the diagnosis and
management of LTBI requires a quality control programme for
the diagnostic tests used and regular reporting of treatment
outcomes, including compliance. The government needs to
develop models for cost covering of services – diagnostic and
clinical – provided in the private sector within the framework of
universal health coverage (UHC), as has already been done
successfully in countries such as Pakistan, Bangladesh, India,
and Indonesia. UHC means that all people have access to the health
services they need, when and where they need them, without
financial hardship, and this is part of the SDGs (WHO UHC, 2019).
UHC was addressed by a high-level meeting at the United Nations
General Assembly (UNGA) on September 23, 2019 (WHO UNGA,
2019). The Oman Minister of Health, at a side event held on
multisectoral action to end TB by the WHO and the Russian
Federation at the UNGA, stressed the need for greater commitment
in reaching vulnerable groups such as migrants. He called for
greater partnership across all sectors, including the private sector,
to reach this goal.
The private health sector in Oman is capable of and willing to
handle screening for LTBI and follow-up treatment. The key is the
financial model. There are two options: (1) an insurance paid
model where the employer responsible for the migrant worker has
insurance that covers the diagnosis and management of LTBI; and
(2) a model where the private sector clinics are reimbursed by the
government after the price for the service has been negotiated.
The incentives that could be offered could include accreditation
and positive branding of collaborative private sector health
facilities, as well as access to new tools such as rapid diagnostic
tests and new drugs that are currently only available in the public
sector.
Developing molecular characterization by whole genome sequencing
(WGS) to uncover transmission routes and define clusters and detect
genotype resistance
A single study from Oman used spoligotyping to explore the
genetic population structure and clustering of Mtb isolates among
nationals and immigrants (Al-Maniri et al., 2010). The study found
a predominance of the strain families commonly found on the
Indian sub-continent. A high proportion of immigrant strains were
in the same clusters as Omani strains (Al-Maniri et al., 2010).
However, spoligotyping has a very low discriminatory power
compared to WGS.
Genotyping Mtb strains from TB patients over time pro-
vides detailed information on the Mtb transmission dynamics
(Folkvardsen et al., 2017; Andrés et al., 2019), and it is possible
to determine transmission among and between nationalities
(Kamper-Jørgensen et al., 2012a). This information can be used
to optimize the public health management of TB, e.g. by directing
the TB control efforts to specific risk-groups (Karmakar et al.,
2019). A study from Copenhagen found a prevalence rate of APTB of
3% in homeless people identified by sputum culture (Jensen et al.,
2015).
Specifically in Oman, WGS will be useful to determine the
amount of transmission between migrant workers and Omanis and
to identify high-risk groups and hotspots for active TB transmission
within the country.
In addition, systematic use of WGS on all Mtb isolates will
allow the emergence of drug resistance to be monitored and, if
implemented from early liquid culture, could allow the cost of
phenotypic drug sensitivity tests on strains that are fully wild-type
for first-line drugs to be reduced. This strategy will be fully
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drug-susceptibility testing, and systematic screening of contacts
and high-risk groups. The Oman Central Public Health Laboratory
has received a grant from the Oman Research Council on
“Understanding TB transmission and epidemiology using molecu-
lar and geo-spatial methods”, and this will be incorporated into the
routine surveillance in the future.
Patient-centred care including treatment support
The key challenge with programmatic LTBI screening is
compliance with preventive treatment (Frieden and Sbarbaro,
2007; Newell et al., 2006). A recent review of LTBI treatment in
migrants found an overall poor level of compliance (Greenaway
et al., 2018), and one possibility is to extend the community-based
treatment support to cover preventive treatment of LTBI. Adher-
ence to preventive treatment of LTBI infection in Oman was found
to be 42% among HCWs (Khamis et al., 2016). During 2 years of
community-based care delivery in Muscat Governorate, 18 out of
27 Omani pulmonary TB patients included in 2017 and all Omani
nationals with pulmonary TB (n = 16) in 2018, except two new
cases, were on community-based care delivery. There was a
significant reduction in average length of hospital stay for
pulmonary TB patients when compared to previous years (27
days in 2017 and 28 days in 2018, compared to 61 days in 2016).
This may help with the acceptability of preventive treatment
among recipients and may contribute to reduce in-hospital
transmission (Migliori et al., 2019). Even though community
preventive treatment support is not presently offered to people
with LTBI, some form of support to ensure adherence that is either
family or community based would be desirable. This could be
enhanced through the use of digital and video technology. To
increase compliance, the 3-month course with a rifapentin or
rifampicin/isoniazid combination is much preferred.
TB in high-risk groups
Healthcare workers
The United States recently (2019) revised its recommendations
for the surveillance of TB in HCWs, because the risk was deter-
mined to be very low (Sosa et al., 2019). The new recommendations
include baseline (pre-placement) TB screening with an individual
risk assessment and symptom evaluation for all personnel, and
testing with an IGRA or TST for personnel with known exposure to
TB. A recent study from Korea including 3920 HCWs tested with an
IGRA found that 893 (22.8%) had LTBI (Han et al., 2019). The study
also found that the acceptance rate for treatment of LTBI was 64.6%
with 3 months of rifampicin/isoniazid or 4 months of rifampicin.
TB in children
TB cases in Omani children are shown in Table 3. Children pose
unique challenges to TB control programmes, as infection in thisTable 3
Tuberculosis cases in children.
Year Omani Non-Omani Total
2010 9 1 10
2011 9 2 11
2012 12 0 12
2013 10 4 14
2014 6 1 7
2015 9 1 10
2016 6 2 8
2017 7 1 8
2018 6 0 6age group is considered a sentinel event indicating recent
transmission.
The importance and priority of children as a special high-risk
group was highlighted in the WHO End TB Strategy (WHO, 2014). A
recent study estimated that 70% of active TB in children in West
Africa is not diagnosed (TDR, 2019).
The main interventions to prevent new cases in children are
vaccination with the bacillus Calmette-Guérin (BCG) vaccine,
contact tracing and screening for active TB, and treatment of LTBI
(Thomas, 2017). BCG immunization has been terminated in many
low endemic countries due to more side effects than potentially
prevented TB cases. A modelling study of the preventive effect of
BCG vaccination found that a 92% BCG coverage at birth reduced TB
deaths in the global birth cohort by 2.8% (0.1–7.0%, confidence
interval) by age 15 years, and that a 100% coverage at birth reduced
TB deaths by 16.5% (0.7–41.9%, CI) (Roy et al., 2019).
The WHO has strongly recommended treatment for LTBI in
children under 5 years of age who are household contacts of
pulmonary TB cases (WHO, 2018). The performance of screening
tests like the TST and IGRA is poorly documented in children below
2 years of age (Box 1).
There is an increasing need for microbiological (culture)
confirmation of TB disease, which is limited by the paucibacillary
nature of TB in children. Furthermore, the newer rapid molecular
tests are positive in the minority of children, generally <25–40% of
children with TB disease (WHO, 2013; Jenkins et al., 2014).
Screening algorithms and cost-effectiveness
Current LTBI screening is limited by the relatively low PPV of
available tests (Rangaka et al., 2012). Although the PPV appears
better for some IGRA tests compared with the TST (Abubakar et al.,
2018; Gupta et al., 2019), defining reactivation risk varies
significantly by population group. The selection of the population
group determines the efficiency and cost-effectiveness of the
approach (Zenner et al., 2017). Thus screening those at highest
risk of reactivation, such as persons with immunosuppression, is
most cost-effective (Greenaway et al., 2018), and this has led to the
recommendation to focus on these high-risk groups for LTBI
control (WHO, 2017; ECDC, 2018). In the context of TB elimination
and the large estimated numbers of persons with LTBI (Houben
and Dodd, 2016), strategies need to include further groups.
There is a conditional recommendation for screening of a
number of groups, including recent migrants from high incidence
countries (WHO, 2017 LTBI guidelines). A way forward is strati-
fication by epidemiological risk factors (country of origin, time
since arrival), demographic factors (age groups), co-morbidities, or
social risk factors. There is no consensus on thresholds (Greenaway
et al., 2018), and practices vary significantly between countries
(Kunst et al., 2017). The decision on thresholds will depend on
preferences and choices around the population impact of
screening, individual risks and benefits, and cost-effectiveness.Box 1. Fact box.
The End TB targets are:
1 A 95% reduction by 2035 in number of TB deaths
compared with 2015;
2 A 90% reduction by 2035 in TB incidence rate compared
with 2015;
3 Zero TB-affected families facing catastrophic costs due to
TB by 2035 (WHO, 2015).
S66 S. Al Abri et al. / International Journal of Infectious Diseases 92S (2020) S60–S68The UK has chosen its incidence threshold of 150 per 100 000 for
the LTBI programme based on cost-effectiveness studies (Pareek
et al., 2011).
Modelling
Part of the End TB Framework is to empower a strong and self-
sustained TB research community in low- and middle-income
countries with a high TB burden. In Oman, the next revision of the
National TB Strategic Plan will include a national research plan.
The scale of the possible interventions will create a substantial
burden, both in terms of financial costs and population or
healthcare system impact. It is therefore critical that interventions
are designed rationally, and optimized with regards to maximal
impact and minimal burdens. Mathematical modelling provides
important tools for the assessment of potential strategies, and
allows for comparison of a wide range of possible approaches with
relatively minimal resource implications.
In the specific context of Oman, mathematical modelling
approaches could be used to consider the optimal screening
algorithms for latent and active TB in migrants and nationals, and
to evaluate the efficiency of different strategies. This could include
the selection of the most appropriate tests, testing frequency, and
cost-effective approaches to TB incidence reduction. One obvious
task for a modelling analysis is to look at active TB in Omani
nationals in order to provide data indicating whether screening for
latent TB of part of the Omani population would be beneficial.
Modelling can identify high-risk groups in the community,
whether nationals or migrants.
Research
There is a need for operational research aimed at optimizing the
cost-effectiveness of the different interventions, identifying high-
risk groups in the community, follow-up of persons with LTBI
without treatment, and stratification of the risk of developing
active TB based on the strength of the IGRA level or TST reactivity
(Goletti et al., 2018b; Kik et al., 2018).
An obvious research project would be to compare 3 months of
preventive treatment with 1 month (Swindells et al., 2019). The
existing mandatory health investigation including a CXR every 2–4
years will ensure that follow-up is done if the migrant stays in
Oman. This will allow studies on the effectiveness and cost-
effectiveness of active TB screening in combination with LTBI or
LTBI only.
The extension of treatment support services to cover LTBI in
order to increase compliance and a general switch from 6 or 9
months of isoniazid to 3 months of rifapentin or rifampicin/
isoniazid are needed. The planned screening of migrants with
mandatory follow-up every 2 years will also allow Oman to
generate data on the efficacy of the screening assay and efficacy of
the treatment offered, as it is expected that most active TB cases
will develop after arrival.
Models for public–private partnerships to enlarge affordable
coverage for all, need to be developed, tried, and validated. A recent
study from Australia compared central and decentralized man-
agement in TB programmes and concluded that central pro-
grammes were better suited to change and challenges (Degeling
et al., 2019)
Conclusions
Fulfilling the WHO End TB Strategy and the WHO TB Elimination
Framework requires a comprehensive package of strategies. This
review of the challenges of achieving TB elimination in a low
endemic country like Oman with a high number of migrants fromhigh TB endemic countries, clearly shows that screening for LTBI
and the treatment of either all cases with LTBI or high-risk cases, is
a key intervention to reduce new cases. In more high-endemic
settings, the identification of high-risk groups and screening these
for LTBI, followed by preventive treatment, is an initial strategy.
Molecular typing of all new cases in both nationals and
migrants is needed to identify clusters and fully understand the
transmission chains.
The development of public–private partnerships is needed to
handle the burden of screening and treating migrants for LTBI. This
requires political decisions and quality control of diagnostics and
management in private healthcare facilities. With high-level
political commitment in Oman to eliminate TB, the country could
be among the first to achieve TB elimination and serve as a
pathfinder for the region and the world.
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